Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel Gilead SciencesThis Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. Barron'sGilead to acquire cancer therapy developer Arcellx for up to $7.8 billion ReutersHere's Why Shares of Arcellx Are Up Almost 80% Today Yahoo FinanceGilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion WS
